2
FDI World Dental Federation: Global survey shows that less than half (38%) of parents limit their children´s sugary food and drink intake to ensure good oral health
mehr
Storys zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Hitachi Medical Systems Europe Holding AG
Hitachi Medical Systems Europe launches "ARIETTA 750", the new model from the ARIETTA series of diagnostic ultrasound platforms / This model inherited premium class technologies
mehrERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...
mehrNew Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease
Amsterdam (ots/PRNewswire) - - Ferric maltol (FM) was associated with substantially lower use of healthcare resources than IV ferric carboxymaltose (FCM) - IV FCMwas linked to greater productivity loss and disruption to patients' work and family life due to the need for clinic-based IV administration - 50% of ...
mehrMSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020
Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...
Ein DokumentmehrNorgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe
Amsterdam (ots/PRNewswire) - - Norgine to receive upfront payments, undisclosed milestone payments along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today ...
mehrOn World Cancer Day, MSD Switzerland Stands United in Support of its Patients
Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...
Ein DokumentmehrMSD Expands Operations in Switzerland
Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...
Ein DokumentmehrSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Ein DokumentmehrKnight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...
mehrSenzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry
London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be used in Europe's first and biggest national medical cannabis registry, Project TWENTY21, in which an expected 20,000 patients will be enrolled by the end of 2021 creating the largest body of evidence for the efficacy of medical cannabis. Drug Science, the leading independent scientific body on ...
mehrKyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...
mehrLarge Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy (https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz070/5644339?redirectedFrom=fulltext), showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 ...
mehrCOMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers
London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...
mehrUCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
mehrAPR Applied Pharma Research s.a.
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...
mehrQuality-related problems concerning the prescription of medication / Helsana Drug Report
Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...
mehrMerck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...
mehrHitachi Medical Systems Europe Holding AG
2Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI
mehrRESTORE 1st Advanced Therapies Science Meeting
Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...
mehrEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
mehrUEG Week Exhibition Celebrates 50 Years of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer
Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...
mehr- Oral ferric maltol may offer an alternative treatment option to IV iron even in patients who have failed or not tolerated current oral iron treatments[1]
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
mehrFace Up To Rosacea: Galderma Launches Online Support to Empower and Equip Rosacea Sufferers to Discuss the True Burden of Their Disease With a Dermatologist
New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success Lausanne, Switzerland (ots/PRNewswire) - ...
mehrThe International Osteoporosis Foundation (IOF)
2IOF: A fracture every 3 seconds worldwide - That's osteoporosis
mehrThe procedure was performed by Jason M. Scopp, MD, an orthopedic surgeon at Peninsula Orthopaedic Clinic in Salisbury, Maryland
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C(TM) implant, as part of Investigational Device Exemption (IDE) clinical study by Dr. ...
mehrEuropean Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban)
- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical ...
mehrUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
mehrA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
mehrNovo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...
mehr
Vorherige6789101112131415Nächste